Federated Hermes’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Federated Hermes’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-240,762	Closed	-$3.95M	–	2294
2022 Q4	$3.95M	Sell	240,762 -7,404	-3%	-$120K	0.01%	728
2022 Q3	$4.59M	Sell	248,166 -689,151	-74%	-$10.8M	0.01%	691
2022 Q2	$12.3M	Sell	937,317 -1,021,761	-52%	-$11.3M	0.03%	507
2022 Q1	$18.2M	Buy	1,959,078 +1,090,368	+126%	+$9.27M	0.04%	472
2021 Q4	$8.49M	Buy	+868,710	New	+$16.3M	0.02%	693
2021 Q1	–	Sell	-7,177	Closed	-$410K	–	2368
2020 Q4	$410K	Buy	7,177 +7,137	+17,843%	+$423K	﹤0.01%	1565
2020 Q3	$2K	Sell	40 -2,315	-98%	-$113K	﹤0.01%	2114
2020 Q2	$141K	Sell	2,355 -196,148	-99%	-$10.5M	﹤0.01%	1668
2020 Q1	$8.17M	Sell	198,503 -39,774	-17%	-$2.21M	0.02%	523
2019 Q4	$14.8M	Buy	238,277 +230,033	+2,790%	+$10.9M	0.03%	501
2019 Q3	$280K	Buy	+8,244	New	+$244K	﹤0.01%	1537
2018 Q4	–	Sell	-28,756	Closed	-$1.11M	–	2334
2018 Q3	$1.11M	Buy	+28,756	New	+$1.06M	﹤0.01%	1319

Other funds holding DCPH

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Federated Hermes's DCPH Position: Q1 2023 in Review

Federated Hermes sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2023, closing a stake of 240,762 shares — an estimated $3.95M sold.

Federated Hermes first reported a position in DCPH in Q3 2018 and held it in 12 quarters. The position peaked at $18.2M in Q1 2022. 146 funds tracked by Wall St. Rank hold DCPH as of Q1 2023.

Federated Hermes reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Federated Hermes sold 240,762 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $3.95M.
Federated Hermes first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
Federated Hermes's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $18.2M in Q1 2022.
146 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.